Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Research & Development (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of Research & Development data on record, last reported at $21.0 million in Q4 2025.

  • For Q4 2025, Research & Development fell 32.26% year-over-year to $21.0 million; the TTM value through Dec 2025 reached $97.0 million, down 9.35%, while the annual FY2025 figure was $97.0 million, 9.35% down from the prior year.
  • Research & Development reached $21.0 million in Q4 2025 per INDV's latest filing, down from $33.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $33.0 million in Q3 2025 and bottomed at $21.0 million in Q2 2025.